Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics
Entasis Therapeutics Holdings Inc. (ETTX)
Today's Latest Price: $1.78 USD
Updated Dec 2 4:00pm
Add ETTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ETTX Stock Summary
- Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set.
- The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks.
- Entasis Therapeutics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -75.63%, greater than the shareholder yield of merely 6.2% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Entasis Therapeutics Holdings Inc, a group of peers worth examining would be CBIO, CDTX, LOGC, VCNX, and PULM.
- ETTX's SEC filings can be seen here. And to visit Entasis Therapeutics Holdings Inc's official web site, go to www.entasistx.com.
ETTX Stock Price Chart Interactive Chart >
ETTX Price/Volume Stats
| Current price | $1.78 | 52-week high | $5.64 |
| Prev. close | $1.78 | 52-week low | $1.58 |
| Day low | $1.74 | Volume | 1,004,681 |
| Day high | $1.79 | Avg. volume | 214,954 |
| 50-day MA | $1.90 | Dividend yield | N/A |
| 200-day MA | $2.75 | Market Cap | 63.15M |
Entasis Therapeutics Holdings Inc. (ETTX) Company Bio
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.
Loading social stream, please wait...